Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F: The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science. 1987, 237: 888-893. 10.1126/science.3497453.
CAS
PubMed
Google Scholar
Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA: The HIV 'A' (sor) gene product is essential for virus infectivity. Nature. 1987, 328: 728-730. 10.1038/328728a0.
CAS
PubMed
Google Scholar
Fan L, Peden K: Cell-free transmission of Vif mutants of HIV-1. Virology. 1992, 190: 19-29. 10.1016/0042-6822(92)91188-Z.
CAS
PubMed
Google Scholar
Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J: Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 1992, 66: 6489-6495.
PubMed Central
CAS
PubMed
Google Scholar
Blanc D, Patience C, Schulz TF, Weiss R, Spire B: Transcomplementation of VIF-HIV-1 mutants in CEM cells suggests that VIF affects late steps of the viral life cycle. Virology. 1993, 193: 186-192. 10.1006/viro.1993.1114.
CAS
PubMed
Google Scholar
Sakai H, Shibata R, Sakuragi J, Sakuragi S, Kawamura M, Adachi A: Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol. 1993, 67: 1663-1666.
PubMed Central
CAS
PubMed
Google Scholar
von Schwedler U, Song J, Aiken C, Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol. 1993, 67: 4945-4955.
PubMed Central
CAS
PubMed
Google Scholar
Borman AM, Quillent C, Charneau P, Dauguet C, Clavel F: Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol. 1995, 69: 2058-2067.
PubMed Central
CAS
PubMed
Google Scholar
Madani N, Kabat D: An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol. 1998, 72: 10251-10255.
PubMed Central
CAS
PubMed
Google Scholar
Simon JH, Gaddis NC, Fouchier RA, Malim MH: Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med. 1998, 4: 1397-1400. 10.1038/3987.
CAS
PubMed
Google Scholar
Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002, 418: 646-650. 10.1038/nature00939.
CAS
PubMed
Google Scholar
Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 2002, 79: 285-296. 10.1006/geno.2002.6718.
CAS
PubMed
Google Scholar
Rogozin IB, Basu MK, Jordan IK, Pavlov YI, Koonin EV: APOBEC4, a New Member of the AID/APOBEC Family of Polynucleotide (Deoxy)cytidine Deaminases Predicted by Computational Analysis. Cell Cycle. 2005, 4: 1281-1285.
CAS
PubMed
Google Scholar
Teng B, Burant CF, Davidson NO: Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science. 1993, 260: 1816-1819. 10.1126/science.8511591.
CAS
PubMed
Google Scholar
Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J: A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell. 1987, 50: 831-840. 10.1016/0092-8674(87)90510-1.
CAS
PubMed
Google Scholar
Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, Silberman SR, Cai SJ, Deslypere JP, Rosseneu M, et al: Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science. 1987, 238: 363-366. 10.1126/science.3659919.
CAS
PubMed
Google Scholar
Sowden M, Hamm JK, Smith HC: Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing. J Biol Chem. 1996, 271: 3011-3017. 10.1074/jbc.271.6.3011.
CAS
PubMed
Google Scholar
Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL: Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc Natl Acad Sci USA. 1995, 92: 8483-8487. 10.1073/pnas.92.18.8483.
PubMed Central
CAS
PubMed
Google Scholar
Harris RS, Petersen-Mahrt SK, Neuberger MS: RNA Editing Enzyme APOBEC1 and Some of Its Homologs Can Act as DNA Mutators. Mol Cell. 2002, 10: 1247-1253. 10.1016/S1097-2765(02)00742-6.
CAS
PubMed
Google Scholar
Betts L, Xiang S, Short SA, Wolfenden R, Carter CW: Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J Mol Biol. 1994, 235: 635-656. 10.1006/jmbi.1994.1018.
CAS
PubMed
Google Scholar
Wedekind JE, Dance GS, Sowden MP, Smith HC: Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 2003, 19: 207-216. 10.1016/S0168-9525(03)00054-4.
CAS
PubMed
Google Scholar
Xie K, Sowden MP, Dance GS, Torelli AT, Smith HC, Wedekind JE: The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1. Proc Natl Acad Sci USA. 2004, 101: 8114-8119. 10.1073/pnas.0400493101.
PubMed Central
CAS
PubMed
Google Scholar
Iwatani Y, Takeuchi H, Strebel K, Levin JG: Biochemical Activities of Highly Purified, Catalytically Active Human APOBEC3G: Correlation with Antiviral Effect. J Virol. 2006, 80: 5992-6002. 10.1128/JVI.02680-05.
PubMed Central
CAS
PubMed
Google Scholar
Chelico L, Pham P, Calabrese P, Goodman MF: APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA. Nat Struct Mol Biol. 2006, 13: 392-399. 10.1038/nsmb1086.
CAS
PubMed
Google Scholar
Wedekind JE, Gillilan R, Janda A, Krucinska J, Salter JD, Bennett RP, Raina J, Smith HC: Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J Biol Chem. 2006, 281: 38122-38126. 10.1074/jbc.C600253200.
PubMed Central
CAS
PubMed
Google Scholar
Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, Shindo K, Harris RS, Matsuo H: Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature. 2008, 452: 116-119. 10.1038/nature06638.
CAS
PubMed
Google Scholar
Opi S, Takeuchi H, Kao S, Khan MA, Miyagi E, Goila-Gaur R, Iwatani Y, Levin JG, Strebel K: Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol. 2006, 80: 4673-4682. 10.1128/JVI.80.10.4673-4682.2006.
PubMed Central
CAS
PubMed
Google Scholar
Lau PP, Zhu HJ, Baldini A, Charnsangavej C, Chan L: Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene. Proc Natl Acad Sci USA. 1994, 91: 8522-8526. 10.1073/pnas.91.18.8522.
PubMed Central
CAS
PubMed
Google Scholar
Navarro F, Bollman B, Chen H, Konig R, Yu Q, Chiles K, Landau NR: Complementary function of the two catalytic domains of APOBEC3G. Virology. 2005, 333: 374-386. 10.1016/j.virol.2005.01.011.
CAS
PubMed
Google Scholar
Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T: The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem. 2003, 278: 44412-44416. 10.1074/jbc.C300376200.
CAS
PubMed
Google Scholar
Wiegand HL, Doehle BP, Bogerd HP, Cullen BR: A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 2004, 23: 2451-2458. 10.1038/sj.emboj.7600246.
PubMed Central
CAS
PubMed
Google Scholar
Burnett A, Spearman P: APOBEC3G Multimers Are Recruited to the Plasma Membrane for Packaging into Human Immunodeficiency Virus Type 1 Virus-Like Particles in an RNA-Dependent Process Requiring the NC Basic Linker. J Virol. 2007, 81: 5000-5013. 10.1128/JVI.02237-06.
PubMed Central
CAS
PubMed
Google Scholar
Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K: Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol. 2007, 81: 8236-8246. 10.1128/JVI.02694-06.
PubMed Central
CAS
PubMed
Google Scholar
Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR: Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol. 2004, 11: 435-442. 10.1038/nsmb758.
CAS
PubMed
Google Scholar
Suspene R, Sommer P, Henry M, Ferris S, Guetard D, Pochet S, Chester A, Navaratnam N, Wain-Hobson S, Vartanian JP: APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 2004, 32: 2421-2429. 10.1093/nar/gkh554.
PubMed Central
CAS
PubMed
Google Scholar
Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D: The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J Biol Chem. 2006, 281: 29105-29119. 10.1074/jbc.M601901200.
CAS
PubMed
Google Scholar
Khan MA, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, Kao S, Strebel K: Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology. 2007, 4: 48-10.1186/1742-4690-4-48.
PubMed Central
PubMed
Google Scholar
Wang T, Tian C, Zhang W, Luo K, Sarkis PT, Yu L, Liu B, Yu Y, Yu XF: 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol. 2007, 81: 13112-13124. 10.1128/JVI.00892-07.
PubMed Central
CAS
PubMed
Google Scholar
Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: DNA deamination mediates innate immunity to retroviral infection. Cell. 2003, 113: 803-809. 10.1016/S0092-8674(03)00423-9.
CAS
PubMed
Google Scholar
Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS: Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol. 2004, 337: 585-596. 10.1016/j.jmb.2004.01.046.
CAS
PubMed
Google Scholar
Lecossier D, Bouchonnet F, Clavel F, Hance AJ: Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 2003, 300: 1112-10.1126/science.1083338.
CAS
PubMed
Google Scholar
Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003, 424: 99-103. 10.1038/nature01709.
CAS
PubMed
Google Scholar
Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 2003, 424: 94-98. 10.1038/nature01707.
PubMed Central
CAS
PubMed
Google Scholar
Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S: Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 2006, 34: 4677-4684. 10.1093/nar/gkl555.
PubMed Central
CAS
PubMed
Google Scholar
Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, Hance AJ, Clavel F: Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J Virol. 2006, 80: 3679-3683. 10.1128/JVI.80.7.3679-3683.2006.
PubMed Central
CAS
PubMed
Google Scholar
Hache G, Liddament MT, Harris RS: The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J Biol Chem. 2005, 280: 10920-10924. 10.1074/jbc.M500382200.
CAS
PubMed
Google Scholar
Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM: Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol. 2005, 15: 166-170. 10.1016/j.cub.2004.12.068.
CAS
PubMed
Google Scholar
Bogerd HP, Wiegand HL, Doehle BP, Cullen BR: The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology. 2007, 364: 486-493. 10.1016/j.virol.2007.03.019.
PubMed Central
CAS
PubMed
Google Scholar
Jonsson SR, Hache G, Stenglein MD, Fahrenkrug SC, Andresdottir V, Harris RS: Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res. 2006, 34: 5683-5694. 10.1093/nar/gkl721.
PubMed Central
CAS
PubMed
Google Scholar
Hakata Y, Landau NR: Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J Biol Chem. 2006, 281: 36624-36631. 10.1074/jbc.M604980200.
CAS
PubMed
Google Scholar
Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC: Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature. 2005, 435: 108-114. 10.1038/nature03493.
CAS
PubMed
Google Scholar
Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K: Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology. 2007, 4: 61-10.1186/1742-4690-4-61.
PubMed Central
PubMed
Google Scholar
Wang X, Dolan PT, Dang Y, Zheng YH: Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J Biol Chem. 2007, 282: 1585-1594. 10.1074/jbc.M610150200.
PubMed Central
CAS
PubMed
Google Scholar
Goila-Gaur R, Khan M, Miyagi E, Kao S, Opi S, Takeuchi H, Strebel K: HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology. 2008, 372: 136-146. 10.1016/j.virol.2007.10.017.
PubMed Central
CAS
PubMed
Google Scholar
Bennett RP, Diner E, Sowden MP, Lees JA, Wedekind JE, Smith HC: APOBEC-1 and AID are nucleo-cytoplasmic trafficking proteins but APOBEC3G cannot traffic. Biochem Biophys Res Commun. 2006, 350: 214-219. 10.1016/j.bbrc.2006.09.032.
PubMed Central
CAS
PubMed
Google Scholar
Bennett RP, Presnyak V, Wedekind JE, Smith HC: Nuclear Exclusion of the HIV-1 Host Defense Factor APOBEC3G Requires a Novel Cytoplasmic Retention Signal and Is Not Dependent on RNA Binding. J Biol Chem. 2008, 283: 7320-7327. 10.1074/jbc.M708567200.
CAS
PubMed
Google Scholar
Wichroski MJ, Ichiyama K, Rana TM: Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J Biol Chem. 2005, 280: 8387-8396. 10.1074/jbc.M408048200.
CAS
PubMed
Google Scholar
Wichroski MJ, Robb GB, Rana TM: Human Retroviral Host Restriction Factors APOBEC3G and APOBEC3F Localize to mRNA Processing Bodies. PLoS Pathog. 2006, 2: e41-10.1371/journal.ppat.0020041.
PubMed Central
PubMed
Google Scholar
Gallois-Montbrun S, Kramer B, Swanson CM, Byers H, Lynham S, Ward M, Malim MH: Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J Virol. 2007, 81: 2165-2178. 10.1128/JVI.02287-06.
PubMed Central
CAS
PubMed
Google Scholar
Chen K, Huang J, Zhang C, Huang S, Nunnari G, Wang FX, Tong X, Gao L, Nikisher K, Zhang H: Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol. 2006, 80: 7645-7657. 10.1128/JVI.00206-06.
PubMed Central
CAS
PubMed
Google Scholar
Kreisberg JF, Yonemoto W, Greene WC: Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med. 2006, 203: 865-870. 10.1084/jem.20051856.
PubMed Central
CAS
PubMed
Google Scholar
Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC: Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J Biol Chem. 2007, 282: 3539-3546. 10.1074/jbc.M610138200.
CAS
PubMed
Google Scholar
Komohara Y, Suekane S, Noguchi M, Matsuoka K, Yamada A, Itoh K: Expression of APOBEC3G in kidney cells. Tissue Antigens. 2007, 69: 95-98. 10.1111/j.1399-0039.2006.00725.x.
CAS
PubMed
Google Scholar
Argyris EG, Acheampong E, Wang F, Huang J, Chen K, Mukhtar M, Zhang H: The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology. 2007, 367: 440-451. 10.1016/j.virol.2007.06.010.
PubMed Central
CAS
PubMed
Google Scholar
Rose KM, Marin M, Kozak SL, Kabat D: Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J Biol Chem. 2004, 279: 41744-41749. 10.1074/jbc.M406760200.
CAS
PubMed
Google Scholar
Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990, 9: 1551-1560.
PubMed Central
CAS
PubMed
Google Scholar
Watson AJ, Wilburn LM: Inhibition of HIV infection of resting peripheral blood lymphocytes by nucleosides. AIDS Res Hum Retroviruses. 1992, 8: 1221-1227.
CAS
PubMed
Google Scholar
Soros VB, Yonemoto W, Greene WC: Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 2007, 3: e15-10.1371/journal.ppat.0030015.
PubMed Central
PubMed
Google Scholar
Harris SG, Sabio I, Mayer E, Steinberg MF, Backus JW, Sparks JD, Sparks CE, Smith HC: Extract-specific heterogeneity in high-order complexes containing apolipoprotein B mRNA editing activity and RNA-binding proteins. J Biol Chem. 1993, 268: 7382-7392.
CAS
PubMed
Google Scholar
Sowden MP, Ballatori N, Jensen KL, Reed LH, Smith HC: The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors. J Cell Sci. 2002, 115: 1027-1039.
CAS
PubMed
Google Scholar
Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, Esnault C, Heidmann T, Greene WC: High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc Natl Acad Sci USA. 2006, 103: 15588-15593. 10.1073/pnas.0604524103.
PubMed Central
CAS
PubMed
Google Scholar
Gallois-Montbrun S, Holmes RK, Swanson CM, Fernandez-Ocana M, Byers HL, Ward MA, Malim MH: Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol. 2008, 82: 5636-5642. 10.1128/JVI.00287-08.
PubMed Central
CAS
PubMed
Google Scholar
Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, Cichutek K, Flory E, Schumann GG, Munk C: APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem. 2006, 281: 22161-22172. 10.1074/jbc.M601716200.
CAS
PubMed
Google Scholar
Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD: APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol. 2006, 16: 480-485. 10.1016/j.cub.2006.01.031.
CAS
PubMed
Google Scholar
Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR: APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 2006, 34: 89-95. 10.1093/nar/gkj416.
PubMed Central
CAS
PubMed
Google Scholar
Bogerd HP, Wiegand HL, Hulme AE, Garcia-Perez JL, O'Shea KS, Moran JV, Cullen BR: Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc Natl Acad Sci USA. 2006, 103: 8780-8785. 10.1073/pnas.0603313103.
PubMed Central
CAS
PubMed
Google Scholar
Wiegand HL, Cullen BR: Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins. J Virol. 2007, 81: 13694-13699. 10.1128/JVI.01646-07.
PubMed Central
CAS
PubMed
Google Scholar
Xu H, Chertova E, Chen J, Ott DE, Roser JD, Hu WS, Pathak VK: Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology. 2007, 360: 247-256. 10.1016/j.virol.2006.10.036.
CAS
PubMed
Google Scholar
Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 2003, 114: 21-31. 10.1016/S0092-8674(03)00515-4.
CAS
PubMed
Google Scholar
Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH: Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol. 2004, 14: 1392-1396. 10.1016/j.cub.2004.06.057.
CAS
PubMed
Google Scholar
Liddament MT, Brown WL, Schumacher AJ, Harris RS: APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol. 2004, 14: 1385-1391. 10.1016/j.cub.2004.06.050.
CAS
PubMed
Google Scholar
Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, Svarovskaia ES, Brown WL, Mansky LM, Gorelick RJ, Harris RS, Engelman A, Pathak VK: Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration. J Virol. 2007, 81: 7099-7110. 10.1128/JVI.00272-07.
PubMed Central
CAS
PubMed
Google Scholar
Luo K, Wang T, Liu B, Tian C, Xiao Z, Kappes J, Yu XF: Cytidine Deaminases APOBEC3G and APOBEC3F Interact with Human Immunodeficiency Virus Type 1 Integrase and Inhibit Proviral DNA Formation. J Virol. 2007, 81: 7238-7248. 10.1128/JVI.02584-06.
PubMed Central
CAS
PubMed
Google Scholar
Dang Y, Wang X, Esselman WJ, Zheng YH: Identification of APOBEC3DE as Another Antiretroviral Factor from the Human APOBEC Family. J Virol. 2006, 80: 10522-10533. 10.1128/JVI.01123-06.
PubMed Central
CAS
PubMed
Google Scholar
Bishop KN, Holmes RK, Malim MH: Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol. 2006, 80: 8450-8458. 10.1128/JVI.00839-06.
PubMed Central
CAS
PubMed
Google Scholar
Dutko JA, Schafer A, Kenny AE, Cullen BR, Curcio MJ: Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr Biol. 2005, 15: 661-666. 10.1016/j.cub.2005.02.051.
PubMed Central
CAS
PubMed
Google Scholar
Stenglein MD, Harris RS: APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem. 2006, 281: 16837-16841. 10.1074/jbc.M602367200.
CAS
PubMed
Google Scholar
Turelli P, Mangeat B, Jost S, Vianin S, Trono D: Inhibition of hepatitis B virus replication by APOBEC3G. Science. 2004, 303: 1829-10.1126/science.1092066.
PubMed
Google Scholar
Holmes RK, Koning FA, Bishop KN, Malim MH: APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem. 2007, 282: 2587-2595. 10.1074/jbc.M607298200.
CAS
PubMed
Google Scholar
Iwatani Y, Chan DS, Wang F, Maynard KS, Sugiura W, Gronenborn AM, Rouzina I, Williams MC, Musier-Forsyth K, Levin JG: Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 2007, 35: 7096-7108. 10.1093/nar/gkm750.
PubMed Central
CAS
PubMed
Google Scholar
Guo F, Cen S, Niu M, Saadatmand J, Kleiman L: Inhibition of tRNA3Lys-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol. 2006, 80: 11710-11722. 10.1128/JVI.01038-06.
PubMed Central
CAS
PubMed
Google Scholar
Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, Kleiman L: The Interaction of APOBEC3G with Human Immunodeficiency Virus Type 1 Nucleocapsid Inhibits tRNA3Lys Annealing to Viral RNA. J Virol. 2007, 81: 11322-11331. 10.1128/JVI.00162-07.
PubMed Central
CAS
PubMed
Google Scholar
Yang Y, Guo F, Cen S, Kleiman L: Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology. 2007, 365: 92-100. 10.1016/j.virol.2007.03.022.
CAS
PubMed
Google Scholar
Li XY, Guo F, Zhang L, Kleiman L, Cen S: APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem. 2007, 282: 32065-32074. 10.1074/jbc.M703423200.
CAS
PubMed
Google Scholar
Miyagi E, Opi S, Takeuchi H, Khan M, Goila-Gaur R, Kao S, Strebel K: Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J Virol. 2007, 81: 13346-13353. 10.1128/JVI.01361-07.
PubMed Central
CAS
PubMed
Google Scholar
Schumacher AJ, Hache G, Macduff DA, Brown WL, Harris RS: The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol. 2008, 82: 2652-2660. 10.1128/JVI.02391-07.
PubMed Central
CAS
PubMed
Google Scholar
Okeoma CM, Lovsin N, Peterlin BM, Ross SR: APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature. 2007, 445: 927-930. 10.1038/nature05540.
CAS
PubMed
Google Scholar
Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, Chayama K: G to A hypermutation of hepatitis B virus. Hepatology. 2005, 41: 626-633. 10.1002/hep.20580.
CAS
PubMed
Google Scholar
Rosler C, Kock J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsacker F: APOBEC-mediated interference with hepadnavirus production. Hepatology. 2005, 42: 301-309. 10.1002/hep.20801.
PubMed
Google Scholar
Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP: Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA. 2005, 102: 8321-8326. 10.1073/pnas.0408223102.
PubMed Central
CAS
PubMed
Google Scholar
Tanaka Y, Marusawa H, Seno H, Matsumoto Y, Ueda Y, Kodama Y, Endo Y, Yamauchi J, Matsumoto T, Takaori-Kondo A, Ikai I, Chiba T: Anti-viral protein APOBEC3G is induced by interferon-alpha stimulation in human hepatocytes. Biochem Biophys Res Commun. 2006, 341: 314-319. 10.1016/j.bbrc.2005.12.192.
CAS
PubMed
Google Scholar
Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D, Candinas D, Sommer P, Wain-Hobson S, Vartanian JP, Greeve J: Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology. 2006, 43: 1364-1374. 10.1002/hep.21187.
CAS
PubMed
Google Scholar
Lei YC, Hao YH, Zhang ZM, Tian YJ, Wang BJ, Yang Y, Zhao XP, Lu MJ, Gong FL, Yang DL: Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol. 2006, 12: 4492-4497.
PubMed Central
CAS
PubMed
Google Scholar
Nguyen DH, Gummuluru S, Hu J: Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol. 2007, 81: 4465-4472. 10.1128/JVI.02510-06.
PubMed Central
CAS
PubMed
Google Scholar
Baumert TF, Rosler C, Malim MH, von Weizsacker F: Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology. 2007, 46: 682-689. 10.1002/hep.21733.
CAS
PubMed
Google Scholar
Jost S, Turelli P, Mangeat B, Protzer U, Trono D: Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol. 2007, 81: 10588-10596. 10.1128/JVI.02489-06.
PubMed Central
CAS
PubMed
Google Scholar
Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K: Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol. 2005, 79: 5870-5874. 10.1128/JVI.79.9.5870-5874.2005.
PubMed Central
CAS
PubMed
Google Scholar
Tian C, Wang T, Zhang W, Yu XF: Virion packaging determinants and reverse transcription of SRP RNA in HIV-1 particles. Nucleic Acids Res. 2007, 35: 7288-7302. 10.1093/nar/gkm816.
PubMed Central
CAS
PubMed
Google Scholar
Wang T, Tian C, Zhang W, Sarkis PT, Yu XF: Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J Mol Biol. 2008, 375: 1098-1112. 10.1016/j.jmb.2007.11.017.
CAS
PubMed
Google Scholar
Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L: The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem. 2004, 279: 33177-33184. 10.1074/jbc.M402062200.
CAS
PubMed
Google Scholar
Schafer A, Bogerd HP, Cullen BR: Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology. 2004, 328: 163-168. 10.1016/j.virol.2004.08.006.
PubMed
Google Scholar
Alce TM, Popik W: APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem. 2004, 279: 34083-34086. 10.1074/jbc.C400235200.
CAS
PubMed
Google Scholar
Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD: APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol. 2004, 78: 12058-12061. 10.1128/JVI.78.21.12058-12061.2004.
PubMed Central
CAS
PubMed
Google Scholar
Huthoff H, Malim MH: Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation. J Virol. 2007, 81: 3807-3815. 10.1128/JVI.02795-06.
PubMed Central
CAS
PubMed
Google Scholar
Douaisi M, Dussart S, Courcoul M, Bessou G, Vigne R, Decroly E: HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem Biophys Res Commun. 2004, 321: 566-573. 10.1016/j.bbrc.2004.07.005.
CAS
PubMed
Google Scholar
Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF: Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol. 2004, 78: 11841-11852. 10.1128/JVI.78.21.11841-11852.2004.
PubMed Central
CAS
PubMed
Google Scholar
Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK: Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem. 2004, 279: 35822-35828. 10.1074/jbc.M405761200.
CAS
PubMed
Google Scholar
Onafuwa-Nuga AA, Telesnitsky A, King SR: 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. RNA. 2006, 12: 542-546. 10.1261/rna.2306306.
PubMed Central
CAS
PubMed
Google Scholar
Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem. 2004, 279: 7792-7798. 10.1074/jbc.M313093200.
CAS
PubMed
Google Scholar
Stopak K, de Noronha C, Yonemoto W, Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell. 2003, 12: 591-601. 10.1016/S1097-2765(03)00353-8.
CAS
PubMed
Google Scholar
Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med. 2003, 9: 1398-1403. 10.1038/nm946.
CAS
PubMed
Google Scholar
Conticello SG, Harris RS, Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol. 2003, 13: 2009-2013. 10.1016/j.cub.2003.10.034.
CAS
PubMed
Google Scholar
Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med. 2003, 9: 1404-1407. 10.1038/nm945.
CAS
PubMed
Google Scholar
Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 2003, 302: 1056-1060. 10.1126/science.1089591.
CAS
PubMed
Google Scholar
Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K: The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol. 2003, 77: 11398-11407. 10.1128/JVI.77.21.11398-11407.2003.
PubMed Central
CAS
PubMed
Google Scholar
Kao S, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Takeuchi H, Strebel K: Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology. 2007, 369: 329-339. 10.1016/j.virol.2007.08.005.
PubMed Central
CAS
PubMed
Google Scholar
Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF: Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 2004, 18: 2867-2872. 10.1101/gad.1250204.
PubMed Central
CAS
PubMed
Google Scholar
Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D: Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 2004, 18: 2861-2866. 10.1101/gad.1249904.
PubMed Central
CAS
PubMed
Google Scholar
Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF: Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci USA. 2005, 102: 11444-11449. 10.1073/pnas.0502440102.
PubMed Central
CAS
PubMed
Google Scholar
Mehle A, Thomas ER, Rajendran KS, Gabuzda D: A zinc-binding region in Vif binds Cul5 and determines cullin selection. J Biol Chem. 2006, 281: 17259-17265. 10.1074/jbc.M602413200.
CAS
PubMed
Google Scholar
Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF: Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology. 2006, 349: 290-299. 10.1016/j.virol.2006.02.002.
CAS
PubMed
Google Scholar
Paul I, Cui J, Maynard EL: Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci USA. 2006, 103: 18475-18480. 10.1073/pnas.0604150103.
PubMed Central
CAS
PubMed
Google Scholar
Xiao Z, Xiong Y, Zhang W, Tan L, Ehrlich E, Guo D, Yu XF: Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol. 2007, 373: 541-550. 10.1016/j.jmb.2007.07.029.
CAS
PubMed
Google Scholar
Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF: Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 2007, 21: 217-222. 10.1096/fj.06-6773com.
CAS
PubMed
Google Scholar
Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T: Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem. 2005, 280: 18573-18578. 10.1074/jbc.C500082200.
CAS
PubMed
Google Scholar
Dang Y, Siew LM, Zheng YH: APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J Biol Chem. 2008, 283: 13124-13131. 10.1074/jbc.M708728200.
PubMed Central
CAS
PubMed
Google Scholar
Akari H, Fujita M, Kao S, Khan MA, Shehu-Xhilaga M, Adachi A, Strebel K: High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J Biol Chem. 2004, 279: 12355-12362. 10.1074/jbc.M312426200.
CAS
PubMed
Google Scholar
Fujita M, Akari H, Sakurai A, Yoshida A, Chiba T, Tanaka K, Strebel K, Adachi A: Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect. 2004, 6: 791-798. 10.1016/j.micinf.2004.04.011.
CAS
PubMed
Google Scholar
Kao S, Akari H, Khan MA, Dettenhofer M, Yu XF, Strebel K: Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol. 2003, 77: 1131-1140. 10.1128/JVI.77.2.1131-1140.2003.
PubMed Central
CAS
PubMed
Google Scholar
Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K: Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology. 2004, 1: 27-10.1186/1742-4690-1-27.
PubMed Central
PubMed
Google Scholar
Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J: HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J Biol Chem. 2005, 280: 8765-8775. 10.1074/jbc.M409309200.
CAS
PubMed
Google Scholar
Santa-Marta M, Aires da Silva F, Fonseca AM, Rato S, Goncalves J: HIV-1 Vif protein blocks the cytidine deaminase activity of B-cell specific AID in E. coli by a similar mechanism of action. Mol Immunol. 2007, 44: 583-590. 10.1016/j.molimm.2006.02.005.
CAS
PubMed
Google Scholar
Bogerd HP, Doehle BP, Wiegand HL, Cullen BR: A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA. 2004, 101: 3770-3774. 10.1073/pnas.0307713101.
PubMed Central
CAS
PubMed
Google Scholar
Schrofelbauer B, Chen D, Landau NR: A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA. 2004, 101: 3927-3932. 10.1073/pnas.0307132101.
PubMed Central
PubMed
Google Scholar
Mangeat B, Turelli P, Liao S, Trono D: A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem. 2004, 279: 14481-14483. 10.1074/jbc.C400060200.
CAS
PubMed
Google Scholar
Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK: A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA. 2004, 101: 5652-5657. 10.1073/pnas.0400830101.
PubMed Central
CAS
PubMed
Google Scholar
Simon JH, Miller DL, Fouchier RA, Soares MA, Peden KW, Malim MH: The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 1998, 17: 1259-1267. 10.1093/emboj/17.5.1259.
PubMed Central
CAS
PubMed
Google Scholar
Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH: Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol. 1995, 69: 4166-4172.
PubMed Central
CAS
PubMed
Google Scholar
Schrofelbauer B, Senger T, Manning G, Landau NR: Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol. 2006, 80: 5984-5991. 10.1128/JVI.00388-06.
PubMed Central
CAS
PubMed
Google Scholar
Russell RA, Pathak VK: Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol. 2007, 81: 8201-8210. 10.1128/JVI.00395-07.
PubMed Central
CAS
PubMed
Google Scholar
Mehle A, Wilson H, Zhang C, Brazier AJ, McPike M, Pery E, Gabuzda D: Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol. 2007, 81: 13235-13241. 10.1128/JVI.00204-07.
PubMed Central
CAS
PubMed
Google Scholar
Yang S, Sun Y, Zhang H: The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem. 2001, 276: 4889-4893. 10.1074/jbc.M004895200.
PubMed Central
CAS
PubMed
Google Scholar
Miller JH, Presnyak V, Smith HC: The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology. 2007, 4: 81-10.1186/1742-4690-4-81.
PubMed Central
PubMed
Google Scholar
Goncalves J, Korin Y, Zack J, Gabuzda D: Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol. 1996, 70: 8701-8709.
PubMed Central
CAS
PubMed
Google Scholar
Sova P, Volsky DJ: Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol. 1993, 67: 6322-6326.
PubMed Central
CAS
PubMed
Google Scholar
Nascimbeni M, Bouyac M, Rey F, Spire B, Clavel F: The replicative impairment of Vif-mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis. J Gen Virol. 1998, 79 (Pt 8): 1945-1950.
CAS
PubMed
Google Scholar
Mansky LM, Preveral S, Selig L, Benarous R, Benichou S: The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J Virol. 2000, 74: 7039-7047. 10.1128/JVI.74.15.7039-7047.2000.
PubMed Central
CAS
PubMed
Google Scholar
Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR: Human Immunodeficiency Virus Type 1 Vpr Induces the Degradation of the UNG and SMUG Uracil-DNA Glycosylases. J Virol. 2005, 79: 10978-10987. 10.1128/JVI.79.17.10978-10987.2005.
PubMed Central
CAS
PubMed
Google Scholar
Kaiser SM, Emerman M: Uracil DNA Glycosylase Is Dispensable for Human Immunodeficiency Virus Type 1 Replication and Does Not Contribute to the Antiviral Effects of the Cytidine Deaminase Apobec3G. J Virol. 2006, 80: 875-882. 10.1128/JVI.80.2.875-882.2006.
PubMed Central
CAS
PubMed
Google Scholar
Willetts KE, Rey F, Agostini I, Navarro JM, Baudat Y, Vigne R, Sire J: DNA repair enzyme uracil DNA glycosylase is specifically incorporated into human immunodeficiency virus type 1 viral particles through a Vpr-independent mechanism. J Virol. 1999, 73: 1682-1688.
PubMed Central
CAS
PubMed
Google Scholar
Priet S, Navarro JM, Gros N, Querat G, Sire J: Differential incorporation of uracil DNA glycosylase UNG2 into HIV-1, HIV-2, and SIV(MAC) viral particles. Virology. 2003, 307: 283-289. 10.1016/S0042-6822(02)00073-9.
CAS
PubMed
Google Scholar
Langlois MA, Neuberger MS: Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J Virol. 2008, 82: 4660-4664. 10.1128/JVI.02469-07.
PubMed Central
CAS
PubMed
Google Scholar
Chen R, Le Rouzic E, Kearney JA, Mansky LM, Benichou S: Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J Biol Chem. 2004, 279: 28419-28425. 10.1074/jbc.M403875200.
CAS
PubMed
Google Scholar
Yang B, Chen K, Zhang C, Huang S, Zhang H: Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J Biol Chem. 2007, 282: 11667-11675. 10.1074/jbc.M606864200.
CAS
PubMed
Google Scholar
Krokan HE, Otterlei M, Nilsen H, Kavli B, Skorpen F, Andersen S, Skjelbred C, Akbari M, Aas PA, Slupphaug G: Properties and functions of human uracil-DNA glycosylase from the UNG gene. Prog Nucleic Acid Res Mol Biol. 2001, 68: 365-386.
CAS
PubMed
Google Scholar
Krokan HE, Drablos F, Slupphaug G: Uracil in DNA – occurrence, consequences and repair. Oncogene. 2002, 21: 8935-8948. 10.1038/sj.onc.1205996.
CAS
PubMed
Google Scholar
Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T: APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology. 2005, 2: 32-10.1186/1742-4690-2-32.
PubMed Central
PubMed
Google Scholar
Lei YC, Tian YJ, Ding HH, Wang BJ, Yang Y, Hao YH, Zhao XP, Lu MJ, Gong FL, Yang DL: N-terminal and C-terminal cytosine deaminase domain of APOBEC3G inhibit hepatitis B virus replication. World J Gastroenterol. 2006, 12: 7488-7496.
PubMed Central
CAS
PubMed
Google Scholar
Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Yatsuji H, Shirakawa K, Takaori-Kondo A, Chayama K: Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol. 2007, 88: 432-440. 10.1099/vir.0.82319-0.
CAS
PubMed
Google Scholar
Pillai SK, Wong JK, Barbour JD: Turning up the volume on mutational pressure: is more of a good thing always better? (a case study of HIV-1 Vif and APOBEC3). Retrovirology. 2008, 5: 26-10.1186/1742-4690-5-26.
PubMed Central
PubMed
Google Scholar
Mulder LC, Harari A, Simon V: Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci USA. 2008, 105: 5501-5506. 10.1073/pnas.0710190105.
PubMed Central
CAS
PubMed
Google Scholar
Aguiar RS, Lovsin N, Tanuri A, Peterlin BM: Vpr.A3A Chimera Inhibits HIV Replication. J Biol Chem. 2008, 283: 2518-2525. 10.1074/jbc.M706436200.
CAS
PubMed
Google Scholar
Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM: Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med. 2006, 203: 41-46. 10.1084/jem.20051512.
PubMed Central
CAS
PubMed
Google Scholar
Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, Rangel ZG, Munson PJ, Wahl SM: Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood. 2007, 110: 393-400. 10.1182/blood-2006-10-051763.
PubMed Central
CAS
PubMed
Google Scholar
Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR: APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem. 2004, 279: 53379-53386. 10.1074/jbc.M408802200.
CAS
PubMed
Google Scholar
Rose KM, Marin M, Kozak SL, Kabat D: Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res Hum Retroviruses. 2005, 21: 611-619. 10.1089/aid.2005.21.611.
CAS
PubMed
Google Scholar
Langlois MA, Beale RC, Conticello SG, Neuberger MS: Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 2005, 33: 1913-1923. 10.1093/nar/gki343.
PubMed Central
CAS
PubMed
Google Scholar
Doehle BP, Schafer A, Cullen BR: Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology. 2005, 339: 281-288. 10.1016/j.virol.2005.06.005.
CAS
PubMed
Google Scholar
Esnault C, Millet J, Schwartz O, Heidmann T: Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 2006, 34: 1522-1531. 10.1093/nar/gkl054.
PubMed Central
CAS
PubMed
Google Scholar
Zhang W, Zhang X, Tian C, Wang T, Sarkis PT, Fang Y, Zheng S, Yu XF, Xu R: Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol. 2008, 10: 112-121.
CAS
PubMed
Google Scholar
Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM: Human APOBEC3F Is Another Host Factor That Blocks Human Immunodeficiency Virus Type 1 Replication. J Virol. 2004, 78: 6073-6076. 10.1128/JVI.78.11.6073-6076.2004.
PubMed Central
CAS
PubMed
Google Scholar
Schumacher AJ, Nissley DV, Harris RS: APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc Natl Acad Sci USA. 2005, 102: 9854-9859. 10.1073/pnas.0501694102.
PubMed Central
CAS
PubMed
Google Scholar
Turelli P, Vianin S, Trono D: The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J Biol Chem. 2004, 279: 43371-43373. 10.1074/jbc.C400334200.
CAS
PubMed
Google Scholar
Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T: APOBEC3G targets specific virus species. J Virol. 2004, 78: 8238-8244. 10.1128/JVI.78.15.8238-8244.2004.
PubMed Central
CAS
PubMed
Google Scholar
Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, Hance AJ, Heidmann T, Schwartz O: APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature. 2005, 433: 430-433. 10.1038/nature03238.
CAS
PubMed
Google Scholar
OhAinle M, Kerns JA, Malik HS, Emerman M: Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J Virol. 2006, 80: 3853-3862. 10.1128/JVI.80.8.3853-3862.2006.
PubMed Central
CAS
PubMed
Google Scholar
Dang Y, Siew LM, Wang X, Han Y, Lampen R, Zheng YH: Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem. 2008, 283: 11606-11614. 10.1074/jbc.M707586200.
PubMed Central
CAS
PubMed
Google Scholar